Evidence map›Paper›PMID 26030050›Full record

ArticleBone marrow transplantation2015

Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection.

R Hanajiri, M Murata, K Sugimoto, M Murase, R Sakemura, T Goto, K Watanabe, N Imahashi, S Terakura, H Ohashi and 6 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

R HanajiriDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
M MurataDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
K SugimotoDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
M MuraseDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
R SakemuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
T GotoDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
K WatanabeDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
N ImahashiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
S TerakuraDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0002-1194-8046
H OhashiClinical Research Center, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
Y AkatsukaDepartment of Hematology, School of Medicine, Fujita Health University, Toyoake, Japan.
S KurahashiDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
K MiyamuraDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
H KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
T NishidaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
T NaoeDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University · JPNational Hospital Organization · JPFujita Health University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In allo-stem cell transplantation (SCT), it is unclear whether donor-specific anti-HLA Abs (DSAs) can actually mediate graft rejection or if they are simply surrogate markers for the cellular immunity that causes graft rejection. Here, we first analyzed a case of cord blood allograft rejection in which DSA and cytotoxic T lymphocyte (CTL) specific for donor HLA-B*54:01 were detected at the time of graft rejection. Both the DSA and CTL inhibited colony formation by unrelated bone marrow mononuclear cells sharing HLA-B*54:01, suggesting that the humoral and cellular immune responses were involved in the graft rejection. Interestingly, the DSA and CTL were also detected in cryopreserved pre-transplant patient blood, raising a hypothesis that the presence of anti-HLA Abs could be an indicator for corresponding HLA-specific T cells. We then evaluated the existence of HLA-specific CD8(+) T cells in other patient blood specimens having anti-HLA class I Abs. Interferon-γ enzyme-linked immunospot assays clearly confirmed the existence of corresponding HLA-specific T-cell precursors in three of seven patients with anti-HLA Abs. In conclusion, our data demonstrate that integrated humoral and cellular immunity recognizing the same alloantigen of the donor can mediate graft rejection in DSA-positive patients undergoing HLA-mismatched allo-SCT. Further studies generalizing our observation are warranted.

Indexed as

Cord Blood Stem Cell TransplantationImmunity, CellularImmunity, HumoralLeukemia, Myeloid, AcuteAllograftsCD8-Positive T-LymphocytesGraft RejectionHLA-B AntigensHumansMaleMiddle AgedHLA-B Antigens

Identifiers

PMID26030050
OpenAlexW1570951303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.